Table 2.
Summary of base case results and subgroup analyses
| Bevacizumab plus paclitaxel | Paclitaxel alone | Difference | |
|---|---|---|---|
| Life years gained | |||
| Overall population | 2.993 | 2.272 | 0.721 |
| HR+ | 3.504 | 2.495 | 1.009 |
| Triple negative | 1.971 | 1.510 | 0.461 |
| QALYs gained | |||
| Overall population | 2.006 | 1.523 | 0.483 |
| HR+ | 2.327 | 1.674 | 0.652 |
| Triple negative | 1.341 | 1.015 | 0.327 |
| Total lifetime costs, EUR | |||
| Overall population | 54,315 | 26,925 | 27,390 |
| HR+ | 61,805 | 29,350 | 32,454 |
| Triple negative | 40,246 | 18,391 | 21,856 |
| ICER, EUR per QALY gained | |||
| Overall population | 56,721 | ||
| HR+ | 49,749 | ||
| Triple negative | 66,874 | ||
| ICER, EUR per life year gaine | |||
| Overall population | 38,003 | ||
| HR+ | 32,171 | ||
| Triple negative | 47,447 | ||
HR+ hormone receptor positive, ICER incremental cost-effectiveness ratio, QALYs quality adjusted life years